UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  FORM 10-K  [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the Fiscal Year Ended March 31, 2020 OR  [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from: _________ to _________  KYTO TECHNOLOGY AND LIFE SCIENCE, INC. (Exact name of registrant as specified in its charter)  DELAWARE000-5039065-1086538(State or Other Jurisdiction(Commission(I.R.S. Employerof Incorporation)File Number)Identification No.)  13050LaPaloma Road, Los Altos Hills, CA 94022 (Address of Principal Executive Office) (Zip Code)  (408) 313 5830 (Registrant’s telephone number, including area code)  Securities registered pursuant to Section 12(g) of the Act:  COMMON STOCK, $0.01 PAR VALUE (Title of Class)  Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [   ] No [X]  Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [   ] No [X]  Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [   ]  Check if there is no disclosure of delinquent filers pursuant to Item 405 of Regulation S-K contained in this form, and no disclosure will be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [   ]  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  Large accelerated filer[   ]Accelerated filer[   ]Non-accelerated filer[   ]Smaller reporting company[X]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ] No [X]  The aggregate market value of the voting common stock held by non-affiliates of the Registrant at the close of the second quarter on September 30, 2019, was approximately $973,856.  The Registrant had 5,836,832 shares of common stock, $0.01 par value per share, outstanding on April 30, 2020.  1     TABLE OF CONTENTS FORM 10-K FOR FISCAL YEAR ENDED MARCH 31, 2020  PagePART IITEM 1.Business3ITEM 2.Properties3ITEM 3.Legal Proceedings3ITEM 4.Mine Safety Disclosure3PART IIITEM 5.Market for Registrants Common Equity and Related Stockholder Matters4ITEM 6Selected Financial Data5ITEM 7.Management’s Discussion and Analysis of Financial Condition and Results of Operation6ITEM 8.Financial Statements and Supplementary Data9ITEM 9.Changes In and Disagreements with Accountants on Accounting and Financial Disclosure9ITEM 9A.Controls and Procedures9ITEM 9BOther Information10PART IIIITEM 10.Directors, Executive Officers, Promoters and Control Persons;
Compliance with Section 16(a) of the Exchange Act11ITEM 11.Executive Compensation12ITEM 12.Security Ownership of Certain Beneficial Owners and Management13ITEM 13.Certain Relationships and Related Transactions14ITEM 14.Principal Accountant Fees and Services14PART IVITEM 15.Exhibits and Financial Statement Schedules15Signatures17  2     PART I  ITEM 1. BUSINESS  (A) BUSINESS DEVELOPMENT  .Kyto Technology and Life Science, Inc. (the "Company") was formed as a Florida corporation on March 5, 1999 under the name of B Twelve Inc. In August 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019 the Company was re-incorporated as a Delaware company.  The Company was originally formed to acquire and develop innovative minimally toxic and non-immunosuppressive proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been looking at a number of strategies to become active. In April, 2018, the Board adopted a new business plan focused on the development of early stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, and successful entrepreneurs across a number of technology and life science products and markets and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early stage investing, the Company works with angel investment groups and participates only after these groups have completed due diligence and committed to invest, and does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the Companies in which it invests. The Company plans to generate revenue from realised gains from the sale of the businesses in which it has invested.  Generally, it is expected that investments will be realised from an exit within a period of four years following investment. Such sales are outside its control and depend on M&A transactions which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. The Company currently has approximately $30,000 in the bank and is now actively marketing the first $3 million tranche of a Series B round with a target close date of September 2020.  The Company has no regular employees, full-time or part-time. The chief executive officer of Kyto Technology and Life Science, Inc. is acting as a consultant to the Company and does not receive contractual compensation for his services in the form of cash. In the year ended March 31, 2020 he was granted 800,000 stock options as incentive compensation and an ex gratia bonus of $216,000 in recognition of his performance in raising funding, performance of due diligence, and making investments.  B) REPORTS TO SECURITY HOLDERS  The Bylaws of Kyto Technology and Life Science, Inc. are silent regarding an annual report to shareholders. Kyto Technology and Life Science, Inc. is a reporting company and files reports with the U.S. Securities and Exchange Commission (SEC). The Company is required to file quarterly reports (Form 10-Q) and an annual report (Form 10-K) with the SEC. The annual report includes audited financial statements.  Any materials that the Company filed with the Securities and Exchange Commission may be read and copied at the SEC's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. Further, you may obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SECD-0330. The Company is an electronic filer and the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Commission. That site is http://www.sec.gov.  ITEM 2. DESCRIPTION OF PROPERTY  The Company operates its business virtually from third party premises, or the homes of its directors and officers.  ITEM 3. LEGAL PROCEEDINGS  There is no litigation of any type whatsoever pending or threatened by or against the Company, its officers and directors.  ITEM 4. MINE SAFETY DISCLOSURES  Not Applicable   3     PART II  ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS  The following discussions should be read in conjunction with the financial statements and related notes which are included in this Form 10-K for the year ending March 31, 2020. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to find and realize our investments.  (A) MARKET INFORMATION  As of February 23, 2011, our stock quotation coverage moved from the FINRA operated OTC Bulletin Board to the OTC Markets Group, Inc.'s OTCQB under the same symbol "KBPH."  Our common stock has traded on the OTC Bulletin Board (R), or OTCBB, since August 4, 2005. The Company's common stock is quoted on the Electronic Bulletin Board of the OTC market, under the trading symbol KBPH. The following table sets forth, for the calendar quarters indicated, the high and low closing prices for our common stock as reported by OTCBB for fiscal years ended March 31, 2020 and 2019. The quotations reflect inter-dealer prices, without retail mark-up, mark-down, or commission and may not represent actual transactions. The market for the common stock has been sporadic and there have been long periods during which there were few, if any, transactions in the common stock and no reported quotations. Accordingly, reliance should not be placed on the quotes listed below, as the trades and depth of the market may be limited, and therefore, such quotes may not be a true indication of the current market value of the Company's common stock.  Common StockHighLowFiscal Year Ended March 31, 2020First quarter**Second quarter**Third quarter**Fourth quarter$2.25$2.05Fiscal Year Ended March 31, 2019First quarter$2.05$2.05Second quarter**Third quarter**Fourth quarter*** There were no trades in these periods  There were 5,836,832 shares of common stock outstanding as of the end of the fiscal year ended March 31, 2020.  (B) HOLDERS  According to information provided to us by the transfer agent for our shares of Common Stock, as of March 31, 2020, there were 14 holders of record of the shares of Common Stock, including depositories. Based upon information we have received from some of these record owners, we believe there are less than 100 beneficial holders of our shares of Common Stock.  (C) DIVIDENDS  The Company has not paid any dividends to date and has no plans to do so in the foreseeable future.  The holders of Class A and B Preferred Stock shall be entitled to receive out of any funds of the Corporation at a time legally available for the declaration of dividends, dividends at a rate as shall be established within the sole discretion of the Board of Directors and under such terms and conditions as the Board shall prescribe, provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Class A and B Preferred Stock shall be payable before any dividends shall be declared or paid upon or set apart for the Common Stock, all such dividends being noncumulative in nature.   4     (D) SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS.  In April 2018, the Company approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan for the benefit of employees, consultants and directors, with the objective of securing the benefit of services for stock options rather than cash salaries. In the year ended March 31, 2018, the Company granted a total of 2,697,085 options at an exercise price of $0.006 per share. Subsequently through March 31, 2019 all options were vested and exercised.  In July 2019, the majority of the shareholders of the Company approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors.  ITEM 6. SELECTED FINANCIAL DATA  Earnings per share for each of the fiscal
years shown below are based on the
weighted average number of shares outstanding.March 31,
2020March 31,
2019Net Loss$(773,399)$(230,107)Loss Per Share$(0.13)$(0.04)Total assets$2,699,755$1,592,682Total liabilities$32,144$28,950  Year ended March 31Income statement data20202019Investment income--Interest and dividends--Interest from cash and cash equivalents--Fee and other income14,1509,000Total investment income14,1509,000Operating expensesCompensation related expenses--General and admin and other726,503239,082Write down of investment61,046-Net realized gains on investments--Total operating expenses787,549239,082Interest expense-25Net loss(773,399)(230,107)Year ended March 31Balance sheet data20202019Net assets2,667,6111,563,732Number of portfolio companies2818  5     ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATION  (A) PLAN OF OPERATION & LIQUIDITY  Kyto Technology and Life Science, Inc. (the "Company") was formed as a Florida corporation on March 5, 1999 under the name of B Twelve Inc. In August 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019 the Company was re-incorporated as a Delaware company.  The Company was originally formed to acquire and develop innovative minimally toxic and non-immunosuppressive proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been looking at a number of strategies to become active. In April, 2018, the Board adopted a new business plan focused on the development of early stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, and successful entrepreneurs across a number of technology and life science products and markets and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early stage investing, the Company works with angel investment groups and participates only after these groups have completed due diligence and committed to invest, and does not typically invest more than $250,000 in any single investment. The Company plans to generate revenue from realised gains from the sale of the businesses in which it has invested. Generally, it is expected that investments will be realised from an exit within a period of four years following investment. Between April 2018 and September 2019 the Company raised $3,360,000 from sales of Series A preferred stock and between October 2019 and March 2020 raised $600,000 from sales of Series B Preferred stock. These funds were used for investments, operating expenses, and fundraising activities.  Starting in the final quarter of our fiscal year ended March 31, 2020 the world has suffered from the impact of the Covid 19 virus epidemic which has created isolation, uncertainty, and disruption in business and investment activities including our ability to raise the balance of our planned series B Preferred stock round, and the ability of our portfolio companies to develop their businesses or raise additional funding if required. At March 31, 2020, we had $33,756 in the bank and although we have reduced the amount we spend on fundraising, we will need to raise additional funding during the coming fiscal year to meet expenses and remain a going concern.  (B) RESULTS OF OPERATIONS  Revenue: The Company depends on the emergence of liquidity situations to realize its investments in portfolio companies but does not have any ability to influence such events. During the years ended March 31, 2020 and 2019 there were no liquidation transactions and accordingly the Company did not generate any revenue from investments. The Company also provides advisory services to certain of its portfolio companies and during the years ended March 31, 2020 and 2019, the Company recognized $14,150 and $9,000 revenue, respectively, from advisory fees.  General and Administration expenses: The Company incurred operating expenses of $787,549 and $239,082 in the years ended March 31, 2020 and 2019, respectively. The increase of 229% reflects the increased level of new business activity as the Company raised funding from private placements, and research and evaluation of investment candidates during the year ended March 31, 2020. General and administration expenses include professional fees incurred in the course of SEC filing and compliance, and travel, conference and investor relations fees associated with fund raising and review of investment deal-flow. The principal expense categories were travel, up from $17,000 in the year ended 2019 to $43,000 in the year ended 2020, investor relations and fund raising up from $16,000 in the year ended 2019 to $302,000 in the year ended 2020, and executive bonus up from $0 in the year ended 2019 to $216,000 in the year ended 2020.  In addition, the Company expensed an impairment charge of $61,046 in the year ended March 31, 2020 in respect of one of their investments that had ceased business.  For the years ended March 31, 2020 and 2019, the Company’s net loss was $773,399 and $230,107, respectively.  (C) LIQUIDITY AND CAPITAL RESOURCES  Working capital:  The Company had a working capital surplus of $2,667,611 and $1,563,732 at March 31, 2020 March 31, 2019, respectively. Cash was $33,756 and $93,634 as of March 31, 2020 and 2019, respectively.  6     Cash from operating activities:  The Company’s cash outflow from operations for the years ended March 31, 2020 and 2019 was $699,882 and $205,225, respectively.  Cash from investing activities:  The Company’s cash outflow from investing activities for the years ended March 31, 2020 and 2019 was $1,228,497 and $1,498,048, respectively.  Cash from financing activities:  The Company’s net cash inflow from financing activities for the years ended March 31, 2020 and 2019 was $1,868,501 and $1,796,903, respectively. During the year ended March 31, 2020, the Company raised from accredited investors $1,270,001 from private placements of Series A Preferred investment units, and $600,000 from private placements of Series B Preferred investment units. During the year ended March 31, 2019, the Company raised from accredited investors $1,770,000 from private placements of Series A Preferred investment units, and $0 from private placements of Series B Preferred investment units.  (D) SIGNIFICANT ACCOUNTING POLICIES  BASIS OF PRESENTATION  The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition, income tax uncertainties, and other contingencies.  The Company’s financial statements are prepared using the specialized accounting principles of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946). In accordance with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments. The Company carries its liabilities at amounts payable, net of unamortized premiums or discounts. The Company does not currently plan to elect to carry its liabilities at fair value. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.  The financial information associated with the March 31, 2020 and 2019 of management, contains all adjustments and eliminations, consisting of only normal recurring adjustments, necessary for a fair presentation in accordance with GAAP.  REVENUE RECOGNITION  The Company derives revenue from the sale of investments and occasional fees earned from the provision of financial advisory services to portfolio investment companies. As a minority, early-stage investor, the Company does not have the ability to manage the timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a guideline, it would expect such events to occur around four years after its investments are made. The Company will book the revenue from investment activities upon completion of sale and receipt of net proceeds, after deducting related transaction expenses. The Company does not recognize any revenue from unrealized gains. The Company is in regular contact with the management of its portfolio investment companies to provide the basis for impairment reviews, and forecasting future revenue and fund raising needs.  USE OF ESTIMATES  In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.  Significant estimates during the fiscal year ended March 31, 2020 and 2019 include the valuation of investment valuation, stock options and warrants.   7     INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE  The Company reviews the performance of the underlying investments including, management reports, press releases, web site announcements and progress reports, Carta equity updates, management interviews and, where accessible, financial reports, to determine their current and future potential value and liquidity. In the event that Management considers the value of an investment to be impaired, the carrying value of the investment will be written down by an impairment charge to reflect Management’s estimated valuation. The Company recognized impairment of one of its investments which was written down by $61,046 in September, 2019. The Company has not experienced any impairment write-downs in any prior or subsequent periods.  The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.  Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.  The Company has established procedures to estimate the fair value of its investments which the company’s board of directors has reviewed and approved. The company will use observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the company will use the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the company’s assumptions about the factors that a market participant would use to value the asset.  For investments for which quoted market prices are not available, which will comprise most of our investment portfolio, fair value will be estimated by using the income or market approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.  In determining the appropriate fair value of an investment using these approaches, the most significant information and assumption may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the project does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparable, the principal market and enterprise values, environmental factors, among other factors.  The estimated fair values will not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.  The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy are defined as follows:  Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities  Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data  Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.  VOLUNTARY CHANGE IN ACCOUNTING PRINCIPLE  During the fourth quarter of fiscal 2020, the Company made a voluntary change in accounting principle by preparing the company’s financial statements using the specialized accounting principles of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946).  8     The Company made this voluntary change in principle because it believes that the Company now meets the characteristics and requirement of being an investment company under ASC 946, and the presentation under ASC 946 better reflects the business purpose and enhances the comparability of its financial statements with many of its industry peers. In accordance with U.S. GAAP, the change has been reflected in the financial statements through retrospective application as follows:  March 31, 2020March 31, 2019Prior toEffect ofPrior toEffect ofChangeChangeAdjustedChangeChangeAdjustedCash$33,756$-$33,756$93,634$-$93,364Receivable500-5001,000-1,000Investment-2,665,4992,665,4991,498,0481,498,048Current assets34,2562,665,499-94,6341,498,048-Investment2,665,499(2,665,499)-1,498,048(1,498,048)-Total assets$2,699,755$-$2,699,755$1,592,682$-$1,592,682  (E) OFF-BALANCE SHEET ARRANGEMENT  None.  ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA  Attached audited financial statements for Kyto Technology and Life Science, Inc. for the fiscal years ended March 31, 2020 and 2019 can be found beginning on page F-1.  ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE  The Company did not change accountants during the year and as of the date of these financial statements there are no disagreements with the findings of their accountants.  ITEM 9A. CONTROLS AND PROCEDURES  Evaluation of Disclosure Controls and Procedures  We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the year ended March 31, 2020 we carried out an evaluation, under the supervision and with the participation of our management, including the principal executive officer and the principal financial officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures were ineffective as of March 31, 2020  Management’s Report on Internal Control over Financial Reporting  Our management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of the financial statements of the Company in accordance with U.S. generally accepted accounting principles, or GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.   9     With the participation of our Chief Executive Officer/ Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2020 based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting as of March 31, 2020 based on the COSO framework criteria. Management has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.  These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness.  In light of this material weakness, we performed additional analyses and procedures in order to conclude that our financial statements for the year ended March 31, 2020 included in this Annual Report on Form 10-K were fairly stated in accordance with US GAAP. Accordingly, management believes that despite our material weaknesses, our financial statements for the year ended March 31, 2020 are fairly stated, in all material respects, in accordance with US GAAP.  This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report on Form 10-K.  Limitations on Effectiveness of Controls and Procedures  Our management, including our Chief Executive Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.  Changes in Internal Controls  During the fiscal year ended March 31, 2019, we engaged a third-party bookkeeping and accounting service to post accounting entries and reconcile our bank accounts. While this creates segregation of duties between the bookkeeping function and management supervision and control, we still remain a small company and therefore do not believe that these changes in our internal control over financial reporting should be regarded as material.  ITEM 9B. OTHER INFORMATION  We do not have any information required to be disclosed in a report on Form 8-K during the fourth quarter of fiscal 2020 that was not reported.  10     PART III  ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT  (A) IDENTIFY DIRECTORS AND EXECUTIVE OFFICERS  NameAgePositionGeorges Benarroch73DirectorPaul Russo77Chief executive officer and directorSimon Westbrook71Chief financial officer  The business experience of the persons listed above during the past five years are as follows:  Mr. GEORGES BENARROCH, DIRECTOR  Mr. Benarroch has been a director of the Company since May 5, 2000. He was elected as President and Chief Executive Officer effective February 27, 2006. Mr. Benarroch is the President and Chief Executive Officer of Comindus Finance Inc. Mr. Benarroch has over 40 years of investment banking as well as money management experience. Mr. Benarroch has raised financing for numerous companies, public as well as private, and has managed investment firms in the USA, Canada and Europe. Also, he has been the CEO of a Canadian multibillion dollar asset management firm. Mr. Benarroch resigned as President and Chief Executive Officer of KBPH on April 26, 2018 but remains as a Director.  Dr. PAUL RUSSO, CHIEF EXECUTIVE OFFICER & DIRECTOR  Dr. Russo is the Co-founder and CEO of Kyto Technology and Life Science, Inc. He is also the Founder & Chairman of GEO Semiconductor (www.geosemi.com) since 2014, after havingserved as Chairman & CEO from its founding in 2008. Dr. Russo also serves as a Director of InBay (www.inbaytech.com) and several other technology ventures (Dynamount, Illuminati, Thrive, and other technology startups). Dr. Russo is heavily involved with the Band of Angels, the Keiretsu Forum and other similar organizations which review over 1,000 start-ups' business plans per year. He is also a Board Advisor to BWG, LLC. Dr. Russo served as an outside director of ATI Technologies from 2001 through its acquisition by AMD in 2006.  Prior to founding GEO Semiconductor, Dr. Russo founded Silicon Optix in 2000, a privately held fabless semiconductor company, serving as its Chairman & CEO through 2008. Prior to Silicon Optix, Dr. Russo was the founder, Chairman and CEO of Genesis Microchip (acquired by ST Micro in 2007) following Genesis Microchip’s NASD IPO in 1998.  Prior to founding Genesis, he was General Manager of the General Electric Microelectronics Center, Senior Manager of General Electric’s Industrial Electronics Development Lab and Head, Microsystems Research at RCA's David Sarnoff Research Center. While at RCA, Dr. Russo worked on the world first CMOS microprocessor and pioneered the first use of microprocessors in global communications, programmable video games, TV manufacturing automation and automotive engine control.  Mr. SIMON WESTBROOK, CHIEF FINANCIAL OFFICER  Effective March 15, 2018, Simon Westbrook was appointed the Company's Chief Financial Officer. In 2009, Mr. Westbrook founded Aargo Inc, a company specializing in financial consulting services to corporations in various tech-related industries. Prior to Aargo, Inc., Mr. Westbrook was CFO of Amber Networks, Inc., and the Chief Financial Officer of Sage, Inc. (NASDAQ: SAGI), a Silicon Valley company specializing in flat panel displays. Before joining Sage, Mr. Westbrook held a number of senior financial positions at Creative Technology (NASDAQ: CREAF), a leading PC multimedia company, and Atari Corp (AMEX: ATC), the video game and home computer company both in the USA and overseas. At various times, he has held positions as an advisory board member of the Silicon Valley Financial Executives Institute, and various technology start-up companies where he has assisted in strategic planning, fund raising and team development. Simon is a Chartered Accountant and holds a Masters in Economics from Trinity College, Cambridge in the UK.  (B) IDENTIFY SIGNIFICANT EMPLOYEES  The Company does not currently have, nor expect to receive a significant contribution from, employees that are not executive officers.   11     (C) FAMILY RELATIONSHIPS  There are no directors, executive officers or persons nominated or persons chosen by the Company to become a director or executive officer of the Company who are directly related to an individual who currently holds the position of director or executive officer or is nominated to one of the said positions.  (D) INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS  There are no material events that have occurred in the last five years that would affect the evaluation of the ability or integrity of any director, person nominated to become a director, executive officer, promoter or control person of the Company.  (E) AUDIT COMMITTEE  The Company has currently no audit committee. The Board of Directors approved the financial statements for the previous year.  ITEM 11. EXECUTIVE COMPENSATION  (A) SUMMARY COMPENSATION TABLE  The following table sets forth all annual and long-term compensation for services in all capacities rendered to Kyto by its executive officers and directors for each of the last two most recently completed fiscal years ended  Annual Compensation in $Long-term compensation
awards in $Payouts
in $Name and principal positionYear
ended
March
31,SalaryBonusOther annual
compensation,
consulting feeSecurities
under
options/SARs
grantedRestricted
Shares or
restricted
share
unitsLT
incentivesGeorges Benarroch,2020$-$-$-$-$-$-Director2019$-$-$-$-$-$-Paul Russo,2020$-$216,000$-$-$-$-Chief executive officer, director2019$-$-$-$-$-$-Simon Westbrook,2020$-$-$60,000$-$-$-Chief financial officer2019$-$-$60,000$-$-$-  OPTION/SAR GRANTS TABLE  Name and positionYear ended
March 31,
2020Options,
beginning
of yearGrantedVestedExercisedOptions,
end of
yearGeorges Benarroch, Director2020-150,00080,959-150,0002019-----Paul Russo, Chief executive officer2020-800,000107,945-800,0002019-2,697,0852,697,0852,697,085-Simon Westbrook, Chief financial officer2020-150,00080,959-150,0002019-----  12     (A) LONG-TERM INCENTIVE ("LTIP") AWARDS TABLE  None  (B) COMPENSATION OF DIRECTORS  All directors hold office until the next annual meeting of stockholders and until their successors have been duly elected and qualified. There are no agreements with respect to the election and compensation of directors. The Board of Directors appoints officers annually and each executive officer serves at the discretion of the Board of Directors. The Company does not have any standing committees at this time.  The Company does not currently maintain insurance for the benefit of the directors and officers of Kyto against liabilities incurred by them in their capacity as directors or officers of Kyto. Kyto does not maintain a pension plan for its employees, officers or directors.  None of the directors or senior officers of Kyto and no associate of any of the directors or senior officers of Kyto was indebted to the Company during the financial period ended March 31, 2020 of Kyto other than for routine indebtedness.  (C) EMPLOYMENT CONTRACTS  None  (D) REPORT ON REPRICING OF OPTIONS/SARS  None  ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT  (A) SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT  The following persons (including any group as defined in Regulation S-B, Section 228.403) are known to the Company, as the issuer, to be beneficial owner of more than five percent (5%) of any class of the said issuer's voting securities.  Title of className & address of beneficial ownerCommon
sharesPercentage
of classCommonComindus Finance Corp, Florida, USA2,697,08546.2%CommonPaul Russo, Los Altos, California, USA2,697,08546.2%  (B) SECURITY OWNERSHIP OF MANAGEMENT  Title of className & address of beneficial ownerCommon
sharesPercentage
of classCommonGeorges Benarroch, Florida, USA (1)2,697,08546.20%CommonPaul Russo, California, USA2,697,08546.20%CommonSimon Westbrook, California, USA-0.00% (1) Includes 1,781,285 shares owned by Comindus Finance Group which is controlled by Mr Benarroch.  (C) CHANGES IN CONTROL  There is no such arrangement which may result in a change in control of the Company.  13     ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS  (A) CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS  Detail of related party transactions are described in notes 3 of the Financial Statements.  At March 31, 2018, a balance of $311,430 was payable to a director, chairman and major shareholder of the Company in respect of expenses and fees incurred by him on behalf of the Company. At June 30, 2018, a total of $314,901 of the related party loans and accrued liabilities were converted into 400,000 investment units (“Units”) consisting of 400,000 shares of Series A preferred stock, and 400,000 Warrants to purchase common stock at $1.20 per share. The units were valued at $0.80 per unit. (See Note 5.) The Company recorded a loss on conversion of related party debt of $0 and $5,099, respectively, during the years ended March 31, 2020 and March 31, 2019.  There were no fees accrued or paid to directors in the years ended March 31, 2020 and 2019. At March 31, 2020 and 2019, the Company had accrued and owed $750 and $2,250, respectively, to Paul Russo for car and telephone allowance. At March 31, 2020 and 2019, the Company had accrued and owed $5,000 and $5,000, respectively to Simon Westbrook for unpaid consulting fees.  (B) TRANSACTIONS WITH PROMOTERS  Georges Benarroch would be considered as a promoter of the Company. Georges Benarroch is the president of Comindus Finance Corp, holding 2,697,085 shares of the Company common stock represented by 46.2% of total issued and outstanding common shares.  ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES  (1) Audit Fees  RBSM LLP, Independent Registered Public Accounting firm billed an aggregate of $29,500 and $30,000 for audit of our annual financial statements for the fiscal years ended March 31, 2020 and 2019. These amounts include the review of our related Forms 10-Q during the years audited.  (2) Audit Related Fees  No other professional services were rendered by RBSM LLP for audit related services rendered during the fiscal years ended March 31, 2020 and 2019.  (3) Tax Fees  No professional services were rendered by RBSM LLP for tax compliance, tax advice, and tax planning the fiscal years ended March 31, 2020 and 2019.   14     ITEM 15. EXHIBITS AND REPORTS ON FORM 10-K  (A) LISTING OF EXHIBITS  EXHIBIT
NUMBERDESCRIPTION3(i)(a)Articles of Incorporation of Kyto Technology and Life Science, Inc.*3(i)(b)Articles of Amendment changing name to Kyto Technology and Life Science, Inc.*3(i)(c)Delaware incorporation and revised articles of incorporation **3(ii)Bylaws of Kyto Technology and Life Science, Inc.*31.1Section 302 Certification of the principal executive officer **31.2Section 302 Certification of the principal financial and accounting officer**32.1Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the principal executive officer **32.2Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the principal financial accounting officer**18.1Auditors preferability letter re adoption of ASC 946 **  * Filed as Exhibit to Company's Form 10-SB on September 12th, 2003, with the Securities and Exchange Commission ** Filed as Exhibit with this Form 10-K.  (B) Code of Ethics  Kyto Technology and Life Science, Inc. will conduct its business honestly and ethically wherever we operate in the world. We will constantly improve the quality of our services, products and operations and will create a reputation for honesty, fairness, respect, responsibility, and integrity, trust and sound business judgment. No illegal or unethical conduct on the part of officers, directors, employees or affiliates is in the company's best interest. Kyto Technology and Life Science, Inc. will not compromise its principles for short-term advantage. The ethical performance of this company is the sum of the ethics of those who work here. Thus, we are all expected to adhere to high standards of personal integrity.  Officers, directors, and employees of the company must never permit their personal interests to conflict, or appear to conflict, with the interests of the company, its clients or affiliates. Officers, directors and employees must be particularly careful to avoid representing Kyto Technology and Life Science, Inc. in any transaction with others with whom there is any outside business affiliation or relationship. Officers, directors, and employees shall avoid using their company contacts to advance their private business or personal interests at the expense of the company, its clients or affiliates.  No bribes, kickbacks or other similar remuneration or consideration shall be given to any person or organization in order to attract or influence business activity. Officers, directors and employees shall avoid gifts, gratuities, fees, bonuses or excessive entertainment, in order to attract or influence business activity.  Officers, directors and employees of Kyto Technology and Life Science, Inc. will often come into contact with, or have possession of, proprietary, confidential or business-sensitive information and must take appropriate steps to assure that such information is strictly safeguarded. This information - whether it is on behalf of our company or any of our clients or affiliates - could include strategic business plans, operating results, marketing strategies, customer lists, personnel records, upcoming acquisitions and divestitures, new investments, and manufacturing costs, processes and methods. Proprietary, confidential and sensitive business information about this company, other companies, individuals and entities should be treated with sensitivity and discretion and only be disseminated on a need-to-know basis.  Misuse of material inside information in connection with trading in the company's securities can expose an individual to civil liability and penalties. Directors, officers, and employees in possession of material information not available to the public are "insiders." Spouses, friends, suppliers, brokers, and others outside the company who may have acquired the information directly or indirectly from a director, officer or employee are also "insiders." The Act prohibits insiders from trading in, or recommending the sale or purchase of, the company's securities, while such inside information is regarded as "material," or if it is important enough to influence you or any other person in the purchase or sale of securities of any company with which we do business, which could be affected by the inside information.  15     The following guidelines should be followed in dealing with inside information:  Until the company has publicly released the material information, an employee must not disclose it to anyone except those within the company whose positions require use of the information.  Employees must not buy or sell the company's securities when they have knowledge of material information concerning the company until it has been disclosed to the public and the public has had sufficient time to absorb the information.  Employees shall not buy or sell securities of another corporation, the value of which is likely to be affected by an action by the company of which the employee is aware and which has not been publicly disclosed.  Officers, directors and employees will seek to report all information accurately and honestly, and as otherwise required by applicable reporting requirements.  Officers, directors and employees will refrain from gathering competitor intelligence by illegitimate means and refrain from acting on knowledge, which has been gathered in such a manner. The officers, directors and employees of Kyto Technology and Life Science, Inc. will seek to avoid exaggerating or disparaging comparisons of the services and competence of their competitors.  Officers, directors and employees will obey all Equal Employment Opportunity laws and act with respect and responsibility towards others in all of their dealings. Officers, directors and employees will remain personally balanced so that their personal life will not interfere with their ability to deliver quality products or services to the company and its clients.  Officers, directors and employees agree to disclose unethical, dishonest, fraudulent and illegal behavior, or the violation of company policies and procedures, directly to management.  Violation of this Code of Ethics can result in discipline, including possible termination. The degree of discipline relates in part to whether there was a voluntary disclosure of any ethical violation and whether or not the violator cooperated in any subsequent investigation.   16     SIGNATURES  In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its be signed on its behalf by the undersigned, thereunto duly authorized.  KYTO TECHNOLOGY AND LIFE SCIENCE, INC.DATE: June 30, 2020By:/ s/ Simon WestbrookName:Simon WestbrookChief Financial Officer  Pursuant to the requirements of the Securities Act of 1933, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.  SignatureTitleDate/s/ Paul RussoChief Executive OfficerJune 30, 2020/s/ Georges BenarrochDirectorJune 30, 2020/s/ Simon WestbrookChief Financial OfficerJune 30, 2020  17     Kyto Technology and Life Science, Inc. Financial Statements Table of Contents  Report of Independent Registered Public Accounting FirmF-1Balance Sheets as of March 31, 2020 and 2019F-2Statements of Operations for the years ended March 31, 2020 and 2019F-3Statement of Stockholders' Deficit for the years ended March 31, 2020 and 2019F-4Statements of Cash Flows for the years ended March 31, 2020 and 2019F-5Schedule of Investment as of March 31, 2020 and 2019F-6Notes to Financial StatementsF-9   18    REPORT OR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  To the Board of Directors and Stockholders of Kyto Technology and Life Science, Inc.  Opinion on the Financial Statements  We have audited the accompanying balance sheets of Kyto Technology and Life Science, Inc. (the Company) as of March 31, 2020 and 2019, and the related statements of operations, stockholders’ equity (deficit), cash flows, and schedule of investment for each of the years in the two year period ended March 31, 2020, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two year period ended March 31, 2020, in conformity with accounting principles generally accepted in the United States of America.  Change in Accounting Principle  As discussed in Note 1 to the financial statements, the Company changed its presentation and disclosure in accordance with ASC 946 in fiscal year 2020.  The Company’s Ability to Continue as a Going Concern  The accompanying financial statements have been assuming the Company will continue as a going concern. As discussed in Note 1 to the accompanying financial statements, the Company has suffered recurring losses from operations, generated negative cash flows from operating activities, has an accumulated deficit that raise substantial doubt about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans in regard these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.  Basis for Opinion  These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.  We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting statements. We believe that our audits provide a reasonable basis for our opinion.  We have served as the Company’s auditor since 2011  /s/ RBSM LLPHenderson, NVJune 30, 2020  F-1     Kyto Technology and Life Science, Inc. Balance Sheets  March 31,March 31,20202019ASSETSCurrent AssetsCash$33,756$93,634Receivables5001,000Investments2,665,4991,498,048Total Assets$2,699,755$1,592,682LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable & accrued liabilities$26,394$21,700Accrued liabilities & loans - related party5,7507,250Total Current Liabilities32,14428,950Commitments and Contingencies--Stockholders' EquityPreferred stock authorized but not designated, $.01 par value 19,800,000 shares, none issued and outstanding as of March 31, 2020 and March 31, 2019--Series A preferred convertible stock, $.01 par value, 4,200,000 shares designated, 4,200,000 and 2,612,500 issued and outstanding as of March 31, 2020 and March 31, 2019, respectively42,00126,125Series B preferred convertible stock, $0.01 par value, 6,000,000 shares designated, 812,500 and none issued and outstanding as of March 31, 2020 and March 31, 2019, respectively8,125-Common stock, $.01 par value, 40,000,000 shares authorized, 5,836,832 issued and outstanding as of March 31, 2020 and March 31 2019, respectively58,36858,368Additional paid-in capital35,943,36934,090,092Accumulated deficit(33,384,252)(32,610,853)Total Stockholders' Equity2,667,6111,563,732Total Liabilities and Stockholders' Equity$2,699,755$1,592,682The accompanying notes are an integral part of these audited financial statements.  F-2     Kyto Technology and Life Science, Inc. Statements of Operations  For the Years Ended March 31,20202019Revenue from sale of services$14,150$9,000Operating ExpensesGeneral and administrative726,503239,082Write-down of investments to market value61,046-Total Operating Expenses787,549239,082Loss from Operations(773,399)(230,082)Interest expense, net-(25)Net Loss before taxes(773,399)(230,107)Net income (tax) benefit--Net Loss$(773,399)$(230,107)Weighted average number of shares outstandingbasic and diluted5,836,8325,836,832Net loss per share - basic and diluted$(0.13)$(0.04)The accompanying notes are an integral part of these audited financial statements.  F-3     Kyto Technology and Life Science, Inc. Statements of Shareholders' Equity (Deficit)  Preferred
A
Stock #Preferred
A
Stock
AmountPreferred
B
Stock #Preferred
B
Stock
AmountCommon
Stock #Common
Stock
AmountAdditional
Paid-in
CapitalAccumulated
DeficitTotalBalance, March
31, 2016-$--$-3,139,747$$ 314$32,063,476$(32,195,990)$(132,200)Net (loss) for
year ended March
31, 2017-------(93,929)(93,929)Balance, March
31, 2017-$--$-3,139,747$314$32,063,476$(32,289,919)$(226,129)Net (loss) for
year ended March
31, 2018------$(31,086)$(90,827)(121,913)Balance, March
31, 2018-$--$-3,139,747$31,400$32,032,390$(32,380,746)$(316,956)Net (loss) for the
year ended March
31, 2019-------(230,107)(230,107)Sale of Series A
Preferred stock at
$0.80 per share2,212,50022,125----1,747,875-1,770,000Series A
Preferred stock
issued for
conversion of
related party debt400,0004,000----316,000-320,000Exercise of
options for
common stock at
$.006 per share----2,697,08526,968(10,786)-16,182Compensation
expense on stock
options------4,613-4,613Balance, March
31, 20192,612,500$26,125-$-5,836,832$58,368$34,090,092$(32,610,853)$1,563,732Net (loss) for the
year ended March
31, 2020-------(773,399)(773,399)Sale of Series A
Preferred stock at
$0.80 per share1,587,50015,876----1,254,125-1,270,001Sale of Series B
Preferred stock at
$0.80 per share--812,5008,125--591,875-600,000Compensation
expense on stock
options------7,277-7,277Balance, March
31, 20204,200,000$42,001812,500$8,1255,836,832$58,368$35,943,369$(33,384,252)$2,667,611The accompanying notes are an integral part of these audited financial statements.  F-4     Kyto Technology and Life Science, Inc. Statements of Cash Flows  For the year
ended
March 31,
2020For the year
ended
March 31,
2019CASH FLOW FROM OPERATING ACTIVITIESNet loss$(773,399)$(230,107)Adjustments to reconcile net loss to net cash used
in operating activitiesLoss on conversion of related party debt-5,099Option compensation expense7,2774,613Write-down of investments to market value61,046-Increase / (decrease) in operating assets and liabilitiesReceivables500(1,000)Prepaid & other current assets-7,500Accounts payable and accrued liabilities4,6948,670Total cash (used in) operating activities(699,882)(205,225)CASH FLOW FROM INVESTING ACTIVITIESPurchase of equity investments(1,228,497)(1,498,048)Total cash used in investing activities(1,228,497)(1,498,048)CASH FLOW FROM FINANCING ACTIVITIESProceeds from sales of Series A Preferred stock1,270,0011,770,000Proceeds from sales of Series B Preferred stock600,000Proceeds from exercise of options for common stock-16,182Advances from related party(1,500)10,721Total cash provided by financing activities1,868,5011,796,903Net increase in cash(59,878)93,630Cash at beginning of period93,6344Cash at end of period$33,756$93,634Supplemental Cash Flow Information:Interest Paid$-$25Taxes Paid$800$800Non Cash Financing and Investing ActivitiesPreferred shares issued for conversion of related party debt$-$320,000The accompanying notes are an integral part of these audited financial statements.  F-5     Kyto Technology and Life Science Inc Consolidated schedule of investments As of March 31, 2020  Portfolio CompanyIndustryInvestment and
approximate ownershipCostFair
valuePercentage
of net assets
(a)SAFE Investment – Not readily marketableCnote Group, IncFintech4.3 % ownership$51,500$51,5001.9%Mitre Medical CorpLife Science0.6 % ownership75,00075,0002.8%Total SAFE Investment – Not readily marketable$126,500$126,5004.7%Preferred Stock Investment – Not readily marketableShyft (FKA Crater Group Inc)Technology3.4 % ownership$51,500$51,5001.9%Colabs IncLife Science5.0 % ownership50,00050,0001.9%Neuroflow IncLife Science7.5 % ownership150,000150,0005.6%FemtoDX IncLife Science42,436 series A preferred stock - 5.0 % ownership100,000100,0003.7%Deep Blue Medical Advances IncLife Science10,431 series A preferred stock - 1.0 % ownership49,99749,9971.9%Otomagnetics IncLife Science3.3 % ownership100,000100,0003.7%Trellis Bioscience LLCLife Science0.5 % ownership50,00050,0001.9%Valfix Medical IncLife Science2.9 % ownership50,00050,0001.9%Trellis Bioscience LLCLife Science0.5 % ownership50,00050,0001.9%Total Preferred Investment – Not readily marketable$651,497$651,49724.4%Common Stock Investment – Not readily marketableBoardwalk TechTechnology150,000 units of common stock and warrant - 4.9 % ownership$73,500$73,5002.8%Total Common Stock Investment – Not readily marketable$73,500$73,5002.8%Other Investment – Not readily marketableExodos Life Sciences LPLife ScienceGeneral Partnership Class A-1 Unit - 1.5 % ownership$206,000$206,0007.7%Enduralock LLCTechnologyUnit of LLC - 1.5 % ownership30,00030,0001.1%Total Other Investment – Not readily marketable$236,000$236,0008.8%  F-6     Kyto Technology and Life Science Inc Consolidated schedule of investments As of March 31, 2020 (Continued)  Convertible Loan Investment – Not readily marketable  Seal Rock Therapeutics, Inc.Life ScienceConvertible note, 5%, no fixed term$78,000$78,0002.9%Achelios Therapeutics Inc.Life ScienceConvertible note, 8%, due December 31, 2021100,000100,0003.7%Sensing Electromagnetic Plus corpTechnologyConvertible note, 6%, due August 29, 202050,00010.0%INBay Technology IncTechnologyConvertible note, 24%, due October 26, 202050,00050,0001.9%Basepaws IncTechnologyConvertible note, 1%, due April 30, 202050,00050,0001.9%Kitotech Medical IncLife ScienceConvertible note, 6%, due December 19, 2020100,000100,0003.7%Sensing Electromagnetic Plus corpTechnologyConvertible note, 5%, due January 24, 202111,04810.0%Cnote Group, IncFintechConvertible note, 4%, due December 18, 202050,00050,0001.9%Promaxo, Inc.Life ScienceConvertible note, 8%, due September 1, 2020250,000250,0009.4%Shyft (FKA Crater Group Inc)TechnologyConvertible note, 8%, due March 18, 202050,00050,0001.9%Achelios Therapeutics Inc.Life ScienceConvertible note, 8%, due December 31, 202125,00025,0000.9%SageMedic CorpLife ScienceConvertible note, 8%, due April 12, 202150,00050,0001.9%Beam Semiconductor IncTechnologyConvertible note, 8%, due June 30, 2020150,000150,0005.6%INBay Technology IncTechnologyConvertible note, 12%, due July 9, 202130,00030,0001.1%Lifewave Biomedical IncLife ScienceConvertible note, 6%, due December 31, 202030,00030,0001.1%Cyberdontics IncLife ScienceConvertible note, 8%, due September 4, 202230,00030,0001.1%Light Line Medical IncLife ScienceConvertible note, 8%, due September 9, 202130,00030,0001.1%Visgenx IncLife ScienceConvertible note, 6%, due December 31, 202030,00030,0001.1%Every Key IncTechnologyConvertible note, 5%, due December 11, 2023100,000100,0003.7%Achelios Therapeutics Inc.Life ScienceConvertible note, 8%, due December 31, 202150,00050,0001.9%Lifewave Biomedical IncLife ScienceConvertible note, 6%, due December 31, 202070,00070,0002.6%Light Line Medical IncLife ScienceConvertible note, 8%, due February 10, 202270,00070,0002.6%INBay Technology IncTechnologyConvertible note, 12%, due February 21, 202250,00050,0001.9%Cyberdontics IncLife ScienceConvertible note, 8%, due February 27, 202335,00035,0001.3%Xpan IncLife ScienceConvertible note, 8%, due March 4, 202250,00050,0001.9%Beam Semiconductor IncTechnologyConvertible note, 8%, due March 5, 202150,00050,0001.9%Total Convertible Loan Investment – Not readily marketable$1,639,048$1,578,00259.2%Total net assets$2,726,545$2,665,49999.9%(a) Percentages are based on net assets of $2,667,611 as of March 31, 2020  F-7     Kyto Technology and Life Science Inc Consolidated schedule of investments As of March 31, 2019  Portfolio CompanyIndustryInvestment and
approximate ownershipCostFair
valuePercentage
of net
assets
(a)SAFE Investment – Not readily marketableCnote Group, IncFintech4.3 % ownership$51,500$51,5003.3%Mitre Medical CorpLife Science0.6 % ownership75,00075,0004.8%Total SAFE Investment – Not readily marketable$126,500$126,5008.1%Preferred Stock Investment – Not readily marketableShyft (FKA Crater Group Inc)Technology3.4 % ownership$51,500$51,5003.3%Colabs IncLife Science5.0 % ownership50,00050,0003.2%Neuroflow IncLife Science7.5 % ownership150,000150,0009.6%FemtoDX IncLife Science42,436 series A preferred stock - 5.0 % ownership100,000100,0006.4%Total Preferred Stock Investment – Not readily marketable$351,500$351,50022.5%Other Investment – Not readily marketableExodos Life Sciences LPLife ScienceGeneral Partnership Class A-1 Unit - 1.5 % ownership$206,000$206,00013.2%Total Other Investment – Not readily marketable$206,000$206,00013.2%Convertible Loan Investment – Not readily marketableSeal Rock Therapeutics, Inc.Life ScienceConvertible note, 5%, no fixed term$78,000$78,0005.0%Achelios Therapeutics Inc.Life ScienceConvertible note, 8%, due December 31, 2021100,000100,0006.4%Sensing Electromagnetic Plus corpTechnologyConvertible note, 6%, due August 29, 202050,00050,0003.2%INBay Technology IncTechnologyConvertible note, 24%, due October 26, 202050,00050,0003.2%Basepaws IncTechnologyConvertible note, 1%, due April 30, 202050,00050,0003.2%Kitotech Medical IncLife ScienceConvertible note, 6%, due December 19, 2020100,000100,0006.4%Sensing Electromagnetic Plus corpTechnologyConvertible note, 5%, due January 24, 202111,04811,0480.7%Cnote Group, IncFintechConvertible note, 4%, due December 18, 202050,00050,0003.2%Promaxo, Inc.Life ScienceConvertible note, 8%, due September 1, 2020250,000250,00016.0%Shyft (FKA Crater Group Inc)TechnologyConvertible note, 8%, due March 18, 202050,00050,0003.2%Achelios Therapeutics Inc.Life ScienceConvertible note, 8%, due December 31, 202125,00025,0001.6%Total Convertible Loan Investment – Not readily marketable$814,048$814,04852.1%Total net assets$1,498,048$1,498,04895.8%(a) Percentages are based on net assets of $1,563,732 as of March 31, 2019  F-8     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  (A) NATURE OF BUSINESS  Kyto Technology and Life Science, Inc. was formed as a Florida corporation on March 5, 1999 under the name of B Twelve Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company.  The Company was originally formed to acquire and develop innovative minimally toxic and non-immunosuppressive proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been looking at a number of strategies to become active. In April, 2018, the Board adopted a new business plan focused on the development of early stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, and successful entrepreneurs across a number of technology and life science products and markets and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early stage investing, the Company works with angel investment groups and participates only after these groups have completed due diligence and committed to invest, and does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the Companies in which it invests. The Company plans to generate revenue from realised gains from the sale of the businesses in which it has invested. Generally, it is expected that investments will be realised from an exit within a period of four years following investment. Such sales are outside its control and depend on M&A transactions which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. In 2018, the Company developed a business plan to make investments in early stage private companies. At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to follow the specialized accounting and reporting guidance of contained therein. Other then making its initial investments in its portfolio companies, the Company does not provide any financial support to any of its investees.  The Company currently has approximately $30,000 in the bank and is now actively marketing the first $3 million tranche of a Series B round with a target close date of September 2020. As at June 12, it has raised $300,000 from the sale of Series B stock. Since general and admin expenses, other than investor relations and executive bonus are quite low, averaging $17,000 per month through the year ended March 31, 2020 and payments for investor fundraising, executive bonuses, and commitments to new investment opportunities are discretionary, the Company believes it will be able to manage its cash flow to match available cash on a case by case basis. However, there is no assurance that the Company will be able to continue as a going concern, and stay at home orders, and general economic uncertainties arising out of the current Covid-19 epidemic create additional l delay and uncertainty.  (B) LIQUIDITY  The Company was originally formed to acquire and develop innovative minimally toxic and non-immunosuppressive proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been looking at a number of strategies to become active. In April, 2018, the Board adopted a new business plan focused on the development of early stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, and successful entrepreneurs across a number of technology and life science products and markets and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early stage investing, the Company works with angel investment groups and participates only after these groups have completed due diligence and committed to invest, and does not typically invest more than $250,000 in any single investment. The Company plans to generate revenue from realised gains from the sale of the businesses in which it has invested. Generally, it is expected that investments will be realised from an exit within a period of four years following investment. Between April 2018 and September 2019 the Company raised $3,360,000 from sales of Series A preferred stock and between October 2019 and March 2020 raised $600,000 from sales of Series B Preferred stock. These funds were used for investments, operating expenses, and fundraising activities. However, in spite of this, there can be no assurance that the Company will be able to continue as a going concern, and stay at home orders, and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delay and uncertainty.  (C) BASIS OF PRESENTATION  The company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition, income tax uncertainties, and other contingencies.  F-9     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)  The company’s financial statements are prepared using the specialized accounting principles of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946). In accordance with this specialized accounting guidance, the company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the company will not apply consolidation or equity method of accounting to its investments. The company carries its liabilities at amounts payable, net of unamortized premiums or discounts. The company does not currently plan to elect to carry its liabilities at fair value. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.  The financial information associated with the March 31, 2020 and 2019 of management, contains all adjustments and eliminations, consisting of only normal recurring adjustments, necessary for a fair presentation in accordance with GAAP.  (D) REVENUE RECOGNITION  The Company derives revenue from the sale of investments and occasional fees earned from the provision of financial advisory services to portfolio investment companies. As a minority, early-stage investor, the Company does not have the ability to manage the timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a guideline, it would expect such events to occur around four years after its investments are made. The Company will book the revenue from investment activities upon completion of sale and receipt of net proceeds, after deducting related transaction expenses. The Company does not recognize any revenue from unrealized gains. The Company is in regular contact with the management of its portfolio investment companies to provide the basis for impairment reviews, and forecasting future revenue and fund raising needs.  (E) INCOME TAXES  The Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 "Accounting for Income Taxes" ("Topic 740"). Under Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date.  (F) USE OF ESTIMATES  In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.  Significant estimates during the fiscal year ended March 31, 2020 and 2019 include the valuation of investment valuation, stock options and warrants.  (G) CASH AND CASH EQUIVALENTS  The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at March 31, 2020 and 2019, respectively.  (H) CONCENTRATIONS  The Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of March 31, 2020 and 2019, the Company did not have any deposits in excess of federally insured limits. The Company has not experienced any losses in such accounts through March 31, 2020 and 2019, respectively.  F-10     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)  (I) STOCK-BASED COMPENSATION  Financial Accounting Standards Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that all equity awards granted to employees and consultants be accounted for at “fair value.” This fair value is measured at grant date for stock settled awards, and at subsequent exercise or settlement for cash-settled awards. Under this method, the Company records an expense equal to the fair value of the options or warrants issued. The fair value is computed using the Black Scholes options pricing model. The Company granted 1,370,000 options to consultants and advisors during the year ended March 31, 2020 (2019 - None).  (J) NET LOSS PER COMMON SHARE  In accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, "Earnings per Share", basic earnings per share is computed by dividing the net income less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings per share is computed by dividing net income less preferred dividends by the weighted average number of common shares outstanding including the effect of common stock equivalents. Common stock equivalents, consisting of preferred stock, stock options and warrants, have not been included in the calculation, as their effect is anti-dilutive for the periods presented.  Number of shares used in
calculation of diluted EPSCommon shares5,836,832Preferred A shares3,805,449Preferred B shares95.753Options435,635Warrants3,805,449Total13,979,118  (K) INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE  The Company reviews the performance of the underlying investments including, management reports, press releases, web site announcements and progress reports, Carta equity updates, management interviews and, where accessible, financial reports, to determine their current and future potential value and liquidity. In the event that Management considers the value of an investment to be impaired, the carrying value of the investment will be written down by an impairment charge to reflect Management’s estimated valuation. The Company recognized impairment of one of its investments which was written down by $61,046 in September, 2019. The Company has not experienced any impairment write-downs in any prior or subsequent periods.  The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.  Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.  The Company has established procedures to estimate the fair value of its investments which the company’s board of directors has reviewed and approved. The company will use observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the company will use the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the company’s assumptions about the factors that a market participant would use to value the asset.   F-11     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)  For investments for which quoted market prices are not available, which will comprise most of our investment portfolio, fair value will be estimated by using the income or market approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.  In determining the appropriate fair value of an investment using these approaches, the most significant information and assumption may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the project does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparable, the principal market and enterprise values, environmental factors, among other factors.  The estimated fair values will not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.  The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy are defined as follows:  Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities  Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data  Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.  (L) SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS  In March 2020, the Company adopted Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946). In accordance with this specialized accounting guidance, the company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the company will not apply consolidation or equity method of accounting to its investments.  Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.  (M) DEFERRED FUNDRAISING EXPENSES  In 2019, the Company commenced a plan to raise a Series B Preferred round of equity to fund its ongoing investment program and cost of operations. Typically, it expects that this plan, from start to finish may take from six to nine months and in order to match the cost and benefits of this process, the Company adopted a policy of capitalizing direct expenses incurred in the course of fund raising with the intention of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At December 31, 2019, the Company has deferred $256,174 of such expenses.  Because of the impact of the Covid-19 virus which caused potential investors to slow down their investment decision making, it became difficult to anticipate the rate of funding and, accordingly, the Company decided to write off all deferred fundraising expenses as at March 31, 2020, and to expense such expenses in future periods.  F-12     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 1 NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)  (N) VOLUNTARY CHANGE IN ACCOUNTING PRINCIPLE  During the fourth quarter of fiscal 2020, the Company made a voluntary change in accounting principle by preparing the company’s financial statements using the specialized accounting principles of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946).  The Company made this voluntary change in principle because it believes that the Company now met the characteristics and requirement of being an investment company under ASC 946, and the presentation under ASC 946 better reflects the business purpose and enhances the comparability of its financial statements with many of its industry peers. In accordance with U.S. GAAP, the change has been reflected in the financial statements through retrospective application as follows:  March 31, 2020March 31, 2019Prior toEffect ofPrior toEffect ofChangeChangeAdjustedChangeChangeAdjustedCash$33,756$-$33,756$93,634$-$93,364Receivable500-5001,000-1,000Investment-2,665,4992,665,499-1,498,0481,498,048Current assets34,2562,665,499-94,6341,498,048-Investment2,665,499(2,665,499)-1,498,048(1,498,048)-Total assets$2,699,755$-$2,699,755$1,592,682$-$1,592,682  NOTE 2 COMMITMENTS AND CONTINGENCIES  The Company has no commitments or contingencies.  NOTE 3 RELATED PARTY TRANSACTIONS  At March 31, 2020 there was an accrued liability for $5,750 in respect of consulting fees, and telephone and travel expenses due to officers of the Company.  NOTE 4EARNINGS PER SHARE  Basic earnings per share are computed by dividing earnings available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect per share amounts that would have resulted if dilutive potential common stock had been converted to common stock. Diluted net loss per share is not reported where the diluted earnings per share would be anti-dilutive. The following reconciles amounts reported in the financial statements for the years ended:  20202019Net loss available to common shareholders$(773,399)$(230,107)Weighted average common shares outstanding5,836,8324,769,369Basic and diluted net loss per share$(0.13)$(0.05)  F-13     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 5 INVESTMENTS  The following table summarizes the Company’s investment portfolio at March 31, 2020 and 2019.  As of March 3120202019Number of portfolio companies2818Fair value$2,665,499$1,498,048Cost$2,726,545$1,498,048% of portfolio at costConvertible notes1,578,00258%$814,04854%Preferred stock651,49724%351,50023%Common stock73,5003%-0%SAFE126,5005%126,5008%Other ownership units236,0009%206,00014%Total$2,665,49998%$1,498,048100%  Our investment portfolio represents approximately 99.9% of our net assets at March 31, 2020 and 95.8% at March 31, 2019. Investments in early stage start up private operating entities, are valued based on available metrics, such as relevant market multiples and comparable company valuations, company specific-financial data including actual and projected results and independent third party valuation estimates. These investments are designated as Level 3 assets.  We focus on making our investments are made in the United States, Canada and Israel.  As of March 31, 2019AmericaCanadaIsraelTotalFair value beginning of year$ 1,448,048$ 50,000$            -$ 1,498,048New investments783,497195,000250,0001,228,497Proceeds from sale of investments----Realized gains----Write down of investment(61,046)--(61,046)Fair value March 31, 2020$ 2,170,499$ 245,000$ 250,000$ 2,665,499As of March 31, 2018AmericaCanadaIsraelTotalFair value beginning of year$               -$           -$            -$               -New investments1,448,04850,000-1,498,048Proceeds from sale of investments----Realized gains----Write down of investment----Fair value March 31, 2019$ 1,448,048$ 50,000$            -$ 1,498,048  Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.  F-14     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 5 INVESTMENTS (CONTINUED)  As of March 31, 2019FintechTechnologyLife scienceTotalFair value beginning of year$ 101,500$ 262,548$ 1,134,000$ 1,498,048New investments-483,500744,9971,228,497Proceeds from sale of investments----Realized gains----Write down of investment-(61,046)-(61,046)Fair value March 31, 2020$ 101,500$ 685,002$ 1,878,997$ 2,665,499As of March 31, 2018FintechTechnologyLife scienceTotalFair value beginning of year$            -$            -$               -$               -New investments101,500262,5481,134,0001,498,048Proceeds from sale of investments----Realized gains----Write down of investment----Fair value March 31, 2019$ 101,500$ 262,548$ 1,134,000$ 1,498,048  We invest in early stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership.  Convertible notesPreferred stockCommon stockSAFEsOther ownership interestsTotalAs of March 31, 2019Fair value beginning of year$ 764,048$ 401,500$ 126,500$            -$ 206,000$ 1,498,048New investments825,000299,997-73,50030,0001,228,497Proceeds from sale of investments------Realized gains------Write down of investment(61,046)----(61,046)Fair value March 31, 2020$ 1,528,002$ 701,497$ 126,500$ 73,500$ 236,000$ 2,665,499Convertible notesPreferred stockCommon stockSAFEsOther ownership interestsTotalAs of March 31, 2018$            --$            -$            -$            -$            -$               -Fair value beginning of year------New investments764,048401,500126,500-206,0001,498,048Proceeds from sale of investments------Realized gains------Write down of investment------Fair value March 31, 2019$ 764,048$ 401,500$ 126,500$            -$ 206,000$ 1,498,048  F-15     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 6 INCOME TAXES  On December 22, 2017, the Tax Cuts and Jobs Act (the TCJA), which significantly modified U.S. corporate income tax law, was signed into law by President Trump. The TCJA contains significant changes to corporate income taxation, including but not limited to the reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and generally eliminating net operating loss carrybacks, allowing net operating losses to carryforward without expiration, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the orphan drug tax credit and changes to the deductibility of research and experimental expenditures that will be effective in the future).  The Company had no income tax provision for the years ended March 31, 2020 and 2019 because the Company had net operating losses for both federal and state tax purposes. The net operating loss carryovers may be subject to annual limitations under Internal Revenue Code Section 382/383, and similar state provisions, should there be a greater than 50% ownership change as determined under the applicable income tax regulations. The amount of the limitation would be determined based on the value of the company immediately prior to the ownership change and subsequent ownership changes could further impact the amount of the annual limitation or eliminate them entirely. An ownership change pursuant to Section 382/383 may have occurred in the past or could happen in the future, such that the NOLs available for utilization could be significantly limited or eliminate them entirely.  A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:  For the years ended March 3120202019Tax benefit at federal statutory rate(21.0)%(21.0)%State income taxes, net of federal benefit(8.0)%(5.5)%Permanent differences-%-%Change in valuation allowance29.0%26.5%Effective income tax rate-%-%  The Company has determined that a valuation allowance for the entire net deferred tax asset is required. A valuation allowance is required if, based on the weight of evidence, it is more likely than not that some or the entire portion of the deferred tax asset will not be realized. After consideration of all the evidence, management has determined that a full valuation allowance is necessary to reduce the deferred tax asset to zero.  The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:  For the years ended March 3120202019Net operating loss carryforwards$5,051,328$6,304,297Current year losses773,399230,107Permanent differences--Gross deferred tax assets$5,824,727$6,534,404Valuation allowance(5,824,727)(6,534,404)Deferred tax asset, net of valuation allowance$-$-  At March 31, 2020 and 2019, the Company had net operating loss carry forwards for federal and state income tax purposes of approximately $5.8 million and $6.5 million, respectively. These loss carryforwards expire within fifteen to twenty years of the respective tax years and may be used to offset future taxable income through 2039.  The TCJA, also introduces a limitation on the amount of NOLs that a corporation may deduct in a single tax year under section 172(a) equal to the lesser of the available NOL carryover or 80 percent of a taxpayer’s pre-NOL deduction taxable income (the “80-percent limitation”). This limitation applies only to losses arising in tax years that begin after Dec. 31, 2017 based upon section 172(e)(1) of the amended statute.  F-16     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 6 INCOME TAXES (CONTINUED)  The CARES Act repeals the 80% income limitation for NOL carryovers that can be deducted in tax years beginning before January 1, 2021.  It also provides that for any taxable year beginning after December 31, 2020, the 80% limitation on taxable income equals 80% of the excess of taxable income over the amount of pre-TCJA NOLs carried to such year, clarifying an interpretive issue that had arisen under the TCJA text.  The utilization of the net operating loss carry forwards is dependent upon the ability to generate sufficient taxable income during the carry forward period. In addition, utilization of these carry forwards may be limited due to ownership changes rules, as defined in the Internal Revenue Code 382/383. The Company has not determined if an ownership change has occurred that would limit the use of the net operating losses or eliminate them entirely.  The Company’s tax returns are subject to examination by tax authorities beginning with the year ended March 31, 2015 (or the tax year ended March 31, 2013 if the Company were to utilize its NOLs).  NOTE 7 EQUITY  PREFERRED STOCK  (A) SERIES A PREFERRED  As of March 31, 2020, there are 4,200,000 shares of Series A preferred stock (“Series A”) designated at a par value of $0.01 per share. The Company has outstanding 4,200,000 shares of Series A Preferred stock Units. During the years ended March 31, 2020 and 2019, the Company sold 1,587,500 and 2,212,500 Units, respectively for cash and in the year ended March 31, 2019 issued 400,000 Units for the conversion of $320,000 of related party debt. The Units consist of one Series A share and one warrant per Unit and sold for $0.80 per unit in a private placement to accredited investors The Series A can either be converted into Common Shares upon listing of the Company on Nasdaq or elect to receive $1.60 per share. In the event of any liquidation or winding up of the Company, the holders of the Series A shall be entitled to receive in preference to the holders of Common Shares a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). All share issuances and obligations are recognized on the books and stock register.  (B) SERIES B PREFERRED  There are also 6,000,000 shares of Series B preferred stock (“Series B”) designated at a par value of $0.01 per share. During the year ended March 31, 2020, the Company sold 812,500 shares to accredited investors for $600,000 in a private placement that commenced in September 2019. The Series B can either be converted into Common Shares upon listing of the Company on Nasdaq or elect to receive $1.60 per share. In the event of any liquidation or winding up of the Company, the holders of the Series B shall be entitled to receive in preference to the holders of Common Shares and Series A, a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference).  (C) COMMON STOCK  The Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of March 31, 2020, and March 31, 2019 a total of 5,836,832 shares of the Company’s common stock were issued and outstanding, respectively.  (D) STOCK OPTIONS  In April 2018, the Company approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan for the benefit of employees, consultants and directors, with the objective of securing the benefit of services for stock options rather than cash salaries. In the year ended March 31, 2018, the Company granted a total of 2,697,085 options at an exercise price of $0.006 per share. During the year ended March 31, 2019, 2,697,085 options vested upon the closing of the private placement and were exercised for $16,182.  In July 2019, the majority of the shareholders of the Company approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. During the year ended March 31, 2020, the Company issued a total of 1,370,000 non-qualified stock options to consultants and advisors vesting over terms from one to four years.  F-17     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 7 EQUITY (CONTINUED)  Number
of optionsWeighted
average
exercise
priceWeighted
average
remaining
life in
yearsOutstanding March 31, 2018-$--Granted2,697,085$0.001.00Exercised(2,697,085)$0.001.00Cancelled-$0.00-Outstanding March 31, 2019-$0.00-Exercisable March 31, 2019-$--  In connection with the grant of stock options the Company recognises the value of the related option expense using the Black Scholes model, with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations. The assumptions used for options granted in the years ended March 31, 2020 and 2019 were as follows:  March 31,
2020March 31,
2019Stock Price at grant date$0.0330.006Exercise Price$0.0330.006Term in Years2.321.00Volatility assumed71%73%Annual dividend rate0.0%0%Risk free discount rate2.00%1.79%  The compensation expense calculated at time of grant is amortised over the vesting period for the options granted. During the year ended March 31, 2020 and March 31, 2019, the Company amortised $7,277 and $4,613, respectively, as option expense.  (E) WARRANTS  In conjunction with the sale of Series A Preferred stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20 per share for a period of three years. The Company values the warrantsusing the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest rate, and volatility.  Number of
warrantsWeighted
average
exercise
priceWeighted
average
remaining
life in
yearsOutstanding March 31, 2018-$--Granted2,612,500$1.203.00Exercised-$0.00-Cancelled-$0.00-Outstanding March 31, 20192,612,500$1.202.41Exercisable March 31, 20192,612,500$-2.41  At March 31, 2020, the value of the warrants was $0 as the Company did not bifurcate the value of Series A Preferred and warrants within the Units sold.  F-18     KYTO TECHNOLOGY AND LIFE SCIENCE, INC. NOTES TO FINANCIAL STATEMENTS MARCH 31, 2020  NOTE 8 FINANCIAL HIGHLIGHTS  Per share data (a)  March 31,
2020March 31,
2019Net asset value$0.46$0.27Net loss$0.13$0.04Net realized and unrealized gain (loss) on investments$(0.01)$-Ratios and Supplemental DataNet assets, end of period$2,667,611$1,563,732Common shares outstanding, end of period5,836,8325,836,832Total operating expenses/net assets29.5 %15.3%Net loss/net assets29.0%14.7%Interest expense and bank fees-%-%  (a) Per Share Data is based on weighted average number of common shares outstanding for the period.  NOTE 9 SUBSEQUENT EVENTS  Since March 31, 2020, the Company has raised $325,000 from the sale of 406,250 Series B Preferred stock units through private placements.  Since March 31, 2020, the Company has invested $150,000 in three additional investment opportunities.  F-19